Tarsus Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 1.42 M

Tarsus Pharmaceuticals, Inc. Depreciation And Amortization is USD 1.42 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 35.67% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • Tarsus Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.04 M, a 168.81% change year over year.
  • Tarsus Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 388.00 K, a 34.26% change year over year.
  • Tarsus Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 289.00 K, a 99.31% change year over year.
  • Tarsus Pharmaceuticals, Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 145.00 K.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased